https://investors.bms.com/iframes/press-releases/press-release-details/2024/FDA-Advisory-Committee-Votes-in-Favor-of-Bristol-Myers-Squibbs-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Multiple-Myeloma-in-Earlier-Lines-of-Therapy/default.aspx
https://myelomaresearchnews.com/news/car-t-cell-therapy-farvykti-favored-earlier-multiple-myeloma-treatment/
The ODAC advisory committee has voted in favour for 2 CAR-T therapies in earlier lines of treatment for multiple myeloma. Voting was convincing, bodes well for future CAR-T therapies in earlier lines of treatment.
https://investors.bms.com/iframes/press-releases/press-release-de...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $6.045M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $22.28K | 6.311M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 78 | 84735861 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86304338 | 23 |
View Market Depth
| Last trade - 14.27pm 25/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |